NCT01975220View on ClinicalTrials.gov

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Healthy
Interventions
DRUG

Empagliflozin/Metformin XR, FDC

Experimental: high dose empagliflozin/metformin XR, FDC tablet

DRUG

Empagliflozin/Metformin XR FDC

Experimental: low dose empagliflozin/metformin XR, FDC tablet

DRUG

25 mg Empagliflozin/1000 mg Metformin XR, FDC

Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet

DRUG

1 tablet Empagliflozin/2 tablets Metformin XR

Active Comparator: 1x empagliflozin/2x metformin XR tablets

DRUG

1 tablet Empagliflozin/3 tablets Metformin XR

Active Comparator: 1x empagliflozin/3x metformin XR tablets

DRUG

1 tablet Empagliflozin/2 tablets Metformin XR

Active Comparator: 1x empagliflozin/2x metformin XR tablets

Trial Locations (1)

Unknown

1276.13.1 Boehringer Ingelheim Investigational Site, Austin

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT01975220 - Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets | Biotech Hunter | Biotech Hunter